Niacin, N-3 Fatty Acids and Insulin Resistance
Source: ClinicalTrials.gov NCT00286234 ↗Summary
Linked Publications (3)
-
Effects of prescription niacin and omega-3 fatty acids on lipids and vascular function in metabolic syndrome: a randomized controlled trial.
-
Effects of niacin and omega-3 fatty acids on the apolipoproteins in overweight patients with elevated triglycerides and reduced HDL cholesterol.
-
Once-daily extended-release niacin lowers serum phosphorus concentrations in patients with metabolic syndrome dyslipidemia.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Serum TG |
233; 157; 176; 156 | — |
| SECONDARY Non-HDL-C |
145; 155; 133; 170 | — |
Eligibility Criteria
Inclusion Criteria
40 and 69 years of age Male or female (without hormonal cycling as described below) BMI > 25 Fasting serum triglycerides > 150 mg/dL Ratio of TG/HDL-C > 3.5
Exclusion Criteria
BMIs > 40 kg/m2 TG > 750 mg/dL HDL-C 126 mg/dL) Use of any dietary supplements providing more than 50 mg of niacin or 100 mg of n-3 FA Use of any herbal preparations or weight-loss products Taking any lipid-lowering drugs for at least four weeks prior to screening for the study Medically-required treatment with nitrates, calcium channel blockers, or adrenergic blocking agents (per the Niaspan package insert) Hemoglobin 145 mg/dL. (This restriction will prevent the randomization of any subject whose LDL-C levels, if assigned to an n-3 FA group, might rise by 10% and thus exceed 160 mg/dL) Known substance abuse Participation in a clinical drug trial anytime during the 30 days prior to screening Anyone whom the investigators judge to be a poor candidate
Data sourced from ClinicalTrials.gov (NCT00286234) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.